| Literature DB >> 30227411 |
Frédéric Amant1,2,3, Linda Nooij4, Daniela Annibali5,6, Anne-Sophie van Rompuy7, Sileny Han6, Heidi van den Bulck8,9, Frédéric Goffin10.
Abstract
In this brief report, we present our experience with 3-weekly paclitaxel-carboplatin chemotherapy for patients with vulvar cancer. Two patients with locally advanced disease had an impressive response allowing standard vulvar cancer surgery. One patient with metastatic disease had local stable disease though it was progressive in the lymph nodes. The available literature is sparse and retrospective. Based on promising results, however, a prospective multicenter study is mandatory in order to obtain full data in a larger series of patients in order to learn the benefits of neoadjuvant paclitaxel-carboplatin and compare the results with chemoradiation.Entities:
Keywords: Advanced vulvar cancer; Chemoradiation; Neoadjuvant chemotherapy; Treatment
Mesh:
Substances:
Year: 2018 PMID: 30227411 DOI: 10.1159/000487435
Source DB: PubMed Journal: Gynecol Obstet Invest ISSN: 0378-7346 Impact factor: 2.031